No Data
No Data
Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation
Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Recent 32% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures
Key Insights Given the large stake in the stock by institutions, Compass Therapeutics' stock price might be vulnerable to their trading decisions 51% of the business is held by the top 8 shareholder
12 Health Care Stocks Moving In Monday's After-Market Session
GainersEntero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. The market value of their outstanding shares is at $7.1 million. Akanda (NASDAQ:AKAN) stock rose
H.C. Wainwright Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright analyst Joseph Pantginis maintains $Compass Therapeutics(CMPX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate o
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics: Bisker-Leib Will Continue to Be Available as Senior Consultant for Next 15 Mos >CMPX
Compass Therapeutics: Bisker-Leib Will Continue to Be Available as Senior Consultant for Next 15 Mos >CMPX
No Data